trial

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

NCTId NCT01043458
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 16 (actual)
Sponsored by Abbott Medical Devices
Primary completion 2010-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2009-11
Primary completion
2010-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ABT-126

Sponsors

Abbott Medical DevicesLead Sponsor

Sites

2 total
Glendale, United StatesSan Antonio, United States

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE1
Primary Completion Date
2010-01
Status
COMPLETED
relationships
The graph out of here
drug
ABT-126
drug
lead_sponsor
Abbott Medical Devices
company
indication
Schizophrenia
indication
Schizophrenia
indication